@UlarSawa Regardless of whether novel or established vaccines, ALL vaccines will require strict pharmacovigilance and postmarketing surveillance upon approval of the vaccines. In addition, prior to release of every lot of approved vaccines, lot release will be conducted. Lot release is the process of evaluating each individual lot of a licensed product before giving approval for its release onto the market.

@BALANCE_VIEW NPRA might wait for WHO approval of the vaccine. Sinopharm is planning to apply to WHO for approval as well...

BALANCE_VIEW It is NOT required....I have evaluated vaccine drug product submissions before. Hence, i know the requirements...

@BALANCE_VIEW It is not part of the requirements. Trust me, i know as i work at NPRA. That clinical trial is just part of the vaccine agreement between China and Malaysia. Nothing more...

@DrHash Ok agreed. I wont post anything here for the next 3 days....See what happens...

Cos its resilient like a bamboo...Unshakeable...

@BALANCE_VIEW No, it is not a requirement to conduct clinical trials in Malaysia for the vaccine to be registered.

IOI Properties Group Bhd said today it is exploring a few proposals on potential investments which are currently at a preliminary stage of discussions, in response to an unusual market activity (UMA) query by Bursa Securities.

In a filing to Bursa today, it said there are no other corporate developments that may account for the sharp rise in its share price.

The group said it is not aware of any rumour or report concerning its business, as well as possible explanation for the UMA.

https://www.theedgemarkets.com/article/response-bursas-uma-query-ioi-properties-says-it-exploring-potential-investments

IOI Properties Group Bhd said today it is exploring a few proposals on potential investments which are currently at a preliminary stage of discussions, in response to an unusual market activity (UMA) query by Bursa Securities.

In a filing to Bursa today, it said there are no other corporate developments that may account for the sharp rise in its share price.

The group said it is not aware of any rumour or report concerning its business, as well as possible explanation for the UMA.

https://www.theedgemarkets.com/article/response-bursas-uma-query-ioi-properties-says-it-exploring-potential-investments

haha

@kamjiat01 Luckily kura2 is still alive...Just hibernating at the moment...

love-hate relationship...

Bamboo products and trade (Source Food and Agricultural Organization of the United Nations).

http://www.fao.org/3/a1243e/a1243e04.pdf

@UlarSawa You are welcome to share articles regarding bamboo. I have just shared one above...

Bamboo: An Alternative Raw Material for Wood and Wood-Based Composites

Bamboo is the most important non-wood species which is abundantly grows in most of the tropical and subtropical zone. It has developed as a specially valuable and superior alternate for wood composite manufactured, such as for pulp and paper, stripboards, matboards, veneer, plywood, particleboard and fiberboard. Moreover, several researches have used it as raw material for structural composites such as Oriented Strand Board (OSB), Glue Laminated Timber (GLT), Parallel Strip Lumber (PSL) and Oriented Strand Lumber (OSL). Nowadays, there are many kinds of bamboo composite are produced and traded in the world. However, there are several differences between bamboo and wood for example macroscopic and microscopic characteristics, chemical composition, physical and mechanical properties. For this reason, the methods, technology and equipment for wood processing cannot be directly applied in bamboo utilization. Further research is noticeably required on the information on bamboo properties, cost-effective technologies and managements. With modern techniques and adapted technologies, bamboo can be processed into a wide range of products which successfully compete with wood and other raw materials in the future.

https://www.researchgate.net/publication/271061918_Bamboo_An_Alternative_Raw_Material_for_Wood_and_Wood-Based_Composites

@UlarSawa No harm promoting both bamboo and vaccine....

https://www.washingtonpost.com/health/2020/12/07/pfizer-vaccine-doses-trump/

A top US scientist overseeing COVID-19 vaccine trials expects a large U.S. study to determine how effective AstraZeneca's experimental inoculation is, following perplexing results from other trials released by the company and partner Oxford University.

AstraZeneca Plc is one of the leading vaccine developers, but interim data released Nov. 23 from trials in Britain and Brazil showed a vastly divergent performance when the vaccine was tested in two different dose combinations.

According to the company, a small group of trial subjects inadvertently received a half dose followed by a full dose, instead of the planned two full doses. In that group, the vaccine proved to be 90% effective at preventing illness. But the larger group that received two full doses showed a 62% success rate.

Although 62% efficacy is above the benchmark set by regulators to declare a COVID-19 vaccine a success, it pales when compared with efficacy of 95% and 94.1% demonstrated in large trials for vaccines from Pfizer Inc and Moderna Inc, respectively.

A U.S. study of AstraZeneca's vaccine involving about 30,000 volunteers is in the works and should produce data by late January.

The dosing in the British trial "wasn't done correctly," Corey maintains. Still, the dosing difference does not fully explain the variation in effectiveness seen in the U.K. and Brazilian trials, he said.

"One of the issues with the Oxford data is that there's a lot of lack of uniformity in the schedule and the dose that makes interpretation of the results difficult at best," he said in a phone interview.

There were also differences in the intervals between doses in the U.K. trial versus the Brazilian trial, as well as significant differences in the age range included in the studies. For example, everyone in the 90% effective group was under the age of 55, a group less susceptible to severe COVID-19.

https://www.livemint.com/science/health/astrazeneca-vaccine-trial-will-clear-confusion-on-how-well-it-works-us-scientist-11607386143374.html

@mikho69 Wlc....

@UlarSawa The core business is bamboo. Vaccine is just dessert...

Yes bamboo business is a cash cow....Increased demand from the huge market within China alone is sufficient to generate profit....

Luckily Kanger has Khairy's support....

--------------------

Kanger says it has MOSTI's support to purchase Covid-19 vaccines for private-sector use
https://www.theedgemarkets.com/article/no-objection-kanger-purchase-covid19-vaccine

Other vaccine counters are going downhill... Kanger still steady....

@NoEmo Actually, it Is not a requirement to conduct local clinical trials of vaccines in Malaysia in order to obtain approval from NPRA, MOH. Approval will be based on assessment of the data from preclinical, phase I, phase II and phase III clinical trials conducted by the manufacturer anywhere in the world.

https://www.theedgemarkets.com/article/two-more-firms-join-vaccine-distribution-club

Sinopharm Vaccine is also Halal. A number of middle eastern countries have already ordered this vaccine, including UAE, Bahrain, Morocco, Egypt and Jordan...

---------------

“Abu Dhabi (UAE)’s ulema council has announce that there is no issue with the halal status of the G24 (Sinopharm) vaccine,” he said.

Sumber: https://setkab.go.id/en/govt-involves-mui-to-ensure-halal-covid-19-vaccine/

@stan88 Sinopharm Vaccine is also Halal. A number of middle eastern countries have already ordered this vaccine, including UAE, Bahrain, Morocco, Egypt and Jordan...

---------------

“Abu Dhabi (UAE)’s ulema council has announce that there is no issue with the halal status of the G24 (Sinopharm) vaccine,” he said.

https://setkab.go.id/en/govt-involves-mui-to-ensure-halal-covid-19-vaccine/

https://www.theedgemarkets.com/article/two-more-firms-join-vaccine-distribution-club

https://www.theedgemarkets.com/article/two-more-firms-join-vaccine-distribution-club

https://www.theedgemarkets.com/article/two-more-firms-join-vaccine-distribution-club

https://www.theedgemarkets.com/article/two-more-firms-join-vaccine-distribution-club

https://www.theedgemarkets.com/article/two-more-firms-join-vaccine-distribution-club

@CCL2020 It is mentioned in this bursa announcement here regarding conversion of Redeemable Convertible Notes

https://disclosure.bursamalaysia.com/FileAccess/viewHtml?e=3106655

@My2020 Wlc..

@NoEmo Correct, the link as i have shared above...

@mikho69 @UlarSawa After digging up all the bursa announcements, the answer is as follows : Total number of shares to be issued for PP is 386,970,684 (Please refer to the link below). Hence, after deducting the no. of PP shares issued for 1st tranche ie. 183,237,544 and no. of PP shares issued for 2nd tranche ie. 195,973,879, the remaining balance should be only 7,759,261 shares left.

However, if we take into account what @x3shphere mentioned above regarding the conversion of redeemable convertible notes (RCN) ie 3,703,703 shares, then total remaining would be 7,759,261 PP + 3,703,703 RCN = 11,462,964 remaining shares (Disclaimer : I have no idea what RCN is and whether it should be added to the number of remaining private placement shares. Perhaps some expert here can enlighten us on this matter)

Kanger should be making the announcement soon regarding the number of shares issued for the 3rd tranche which would be the final tranche and private placement would be complete.

https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3103957

@UlarSawa It is normal practice to spread the issuance of private placement shares over several tranches.

@UlarSawa If you notice Kangers Bursa Announcements, first they will announce the fixed issue price for that particular tranche first (See example of announcement for issue price fixed for 2nd tranche below) followed by announcement of the number of private placement shares issued for 2nd tranche which they did announce subsequently. So they should be announcing the number of private placement shares issued for 3rd tranche anytime soon.

https://www.klsescreener.com/v2/announcements/view/3263299

@UlarSawa It is stated here "Reference is made to the announcements dated 13 October 2020, 21 October 2020, 9 November 2020, 10 November 2020, 17 November 2020, 18 November 2020, 20 November 2020, 24 November 2020, 25 November 2020 and 26 November 2020 in relation to the Private Placement."

https://www.klsescreener.com/v2/announcements/view/3273997

Hmm so whats the correct answer regarding PP. Is it complete or not? There are conflicting answers in this forum...

Is Inix involved in any vaccine deals?

@Will188 Carlsberg stock may be a blue chip stock but it is non shariah-compliant. Kanger is a shariah-compliant stock...

https://www.cyclingnews.com/news/uae-team-emirates-to-be-vaccinated-against-covid-19-at-january-training-camp/

Is it a requirement to announce who the PP investors are in Bursa Malaysia or it is up to the company whether or not to announce ?

@Noobie123 Well said..

@Orlando Thanks for sharing the info regarding PP....

@UlarSawa Yes bamboo is profitable. There is a high demand for bamboo flooring and other bamboo related products within China alone. Currently China continues to be the only economy in the world to show positive growth in 2020 as its GDP is predicted to expand 1.9 percent this year, according to the latest economic outlook released by the International Monetary Fund (IMF).

https://news.cgtn.com/news/2020-10-13/World-GDP-to-drop-4-4-in-2020-IMF--UyNuoUIFlC/index.html#:~:text=China%20continues%20to%20be%20the,Fund%20(IMF)%20on%20Tuesday.

@ularsawaRefer here :

9. RISK FACTORS
Kanger does not expect any material risk arising from the Agreement other than the normal business and industry risks such as regulatory approvals of local authorities, logistics handling of the vaccines and competitors.
Even though Kanger may not have the prior experience to undertake the distribution of Covid- 19 vaccines, Kanger will hire an experienced team to mitigate the risks.

10. There will be no costs due to Sinopharm Hunan Changde, in the event Kanger is unable to enter into any dealership/distributorship agreement(s) for the distribution of Covid-19 vaccines.

https://disclosure.bursamalaysia.com/FileAccess/apbursaweb/download?id=107445&name=EA_GA_ATTACHMENTS

@UlarSawa PP is not within my area of expertise. Perhaps someone here can explain further...

@greenland You are absolutely right that approval can be expedited By NPRA on emergency grounds. There is a new approval procedure / pathway for that was just developed to be applied during pandemic situations...